Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Mucosal Immunol. 2010 Aug 25;4(1):112–120. doi: 10.1038/mi.2010.44

Figure 4. HLA-DQ2.5-derived RTL802 blocks antigen specific T cell proliferation.

Figure 4

Proliferation assays were performed using CD patient biopsy-derived antigen-specific T clones. TCC were pre-incubated with 4 or 8 uM of the study drug DQ2.5-derived RTL802, negative controls “empty” RTL800, DR4-derived RTL361, or buffer alone for 48 hours. (A) TCC364.1.0.14 proliferated in response to TG2-treated gluten (10 ug/ml) or the α-II p1274 (PQPELPYPQPQLPY) peptide (2 uM and 10 uM). (B) TCC387.19 proliferates in response to TG2-treated gluten (10 ug/ml) or the γ-VII p1729 (PQTQQPEQPFPQPQ) peptide (10 ug/ml). EBV-transformed human B cells expressing HLA-DQ2.5 loaded with antigens were used as APCs. The T:APC ratio was 1:1, with 60,000 T cells/well. Antigens used included 10 μg/ml of gluten, TG2-treated gluten, p1274 (PQPELPYPQPQLPY) or p1729 (PQTQQPEQPFPQPQ) gluten-derived peptides. Data from triplicate wells are presented as average CPM +/- SD. A representative example of three individual experiments is shown.